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Background: Depression is now considered to have the highest disability burden of all conditions.  Although 
treatment-resistant depression (TRD) is a key contributor to that burden, there is little understanding of the best 
treatment approaches for those who do not respond adequately to antidepressant treatments and specifically the 
effectiveness of available augmentation approaches.   
Aims: We conducted a systematic review and meta-analysis (Prospero registration CRD42018088009) aiming to 
search and quantify the evidence of psychological and pharmacological augmentation interventions for TRD.   
Methods: Trials where patients with TRD were randomised to at least one augmentation treatment were included, 
where treatment resistance was defined as insufficient response to at least two antidepressant treatments in the 
current episode. Pre-post analysis assessed treatment effectiveness, providing an effect size (ES) independent of 
comparator interventions. 
Results: Of 28 included trials, only 3 investigated psychological treatments, while 25 examined pharmacological 
interventions. Assessing treatment classes, pre-post analyses demonstrated N-methyl-D-aspartate targeting drugs 
to have the highest effect size (ES=1.48, 95%CI 1.25–1.71). Other than aripiprazole (4 studies, ES=1.33, 95%CI 1.23-
1.44) and lithium (3 studies, ES=1.00, 95%CI 0.81-1.20), treatments were each investigated in less than three 
studies. Overall, pharmacological (ES=1.19, 95%CI 1.80-1.30) and psychological (ES=1.43, 95%CI 0.50-2.36) 
therapies yielded higher effect sizes than pill placebo (ES=0.78, 95%CI 0.66-0.91) and psychological control 
(ES=0.94, 95%CI 0.36-1.52).  
Conclusions: Despite being used widely in clinical practice, the evidence for augmentation treatments in TRD is 
sparse. Although pre-post meta-analyses are limited by the absence of direct comparison, this work finds 
promising evidence across treatment modalities. 
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Relevance Statement   
This manuscript is submitted for the “treatment-resistant mood disorders” Themed Issue.  
Despite having substantial burden, treatment-resistant depression (TRD) has received little research attention 
and clinicians do not have consistent guidelines for treating the illness. We systematically reviewed the evidence 
of augmentation treatment effectiveness, since most TRD patients are treated with augmenters. In contrast to 
previous meta-analyses, we focus on the most common clinical TRD definition and provide pre-post effect sizes 
for psychological and pharmacological therapies. Although the evidence is scant (28 randomised trials), findings 
demonstrate effectiveness of aripiprazole and lithium, and particular early-stage promise for ketamine, 




The burden of treatment resistant depression (TRD) is challenging to quantify, TRD having eluded a universal 
definition1 but being prevalent and encompassing considerably greater severity, chronicity, recurrence, 
hospitalisation and comorbidity with both psychiatric and non-psychiatric disorders than non-resistant major 
depressive disorder (MDD)2. Despite this, TRD has been a neglected area of research with numerous reviews 
calling for more comprehensive evidence. Indeed, many of these reviews have considered patients as treatment 
resistant if they have failed one previous treatment trial (in contrast with the most popular guidelines1), in part 
because this represents the inclusion criteria frequently used in clinical trials. One such example examined 
pharmacological augmentation treatments which the majority of TRD patients are treated with in practice3. Only 
when using the less stringent criteria of TRD was there sufficient evidence for a network meta-analysis in 20153, 
and the authors reported significant efficacy of quetiapine, aripiprazole, lithium and thyroid hormone compared 
to placebo. However, this evidence may not apply to patients with more severe TRD. Pre-post analyses have the 
benefit of not requiring a placebo arm and the ability to compare effectiveness estimates between heterogeneous 
treatment approaches4. Additionally, pre-post effect sizes provide good clinical face validity as an estimate of the 
magnitude of effects seen with treatment in practice, incorporating both those specific to the individual modality 
as well as non-specific effects and the passage of time4. 
Objectives 
This review aimed to qualify and quantify the evidence of augmentation treatments for TRD, using the most 
common clinical definition (i.e. ≥2 failed treatments in current episode), and to compare effect sizes (ES) across 
psychological and pharmacological interventions. To our knowledge, this is the first meta-analysis comparing pre-
post treatment effects for all augmentation therapies across the two most popular treatment classes for 
depression in clinical practice. Specifically, our objectives were to: 
1. Determine the efficacy of adjunctive interventions for TRD, through comparisons between treatment category 
(i.e. pharmacological or psychological), class (e.g. antipsychotics, mood stabilisers) and individual treatments.  
2. Provide an indication of the acceptability and tolerability of these treatments. 
 
Methods  
Criteria for considering studies for the review 
The protocol for this systematic review was published via PROSPERO5, where full details of the search are available 
and reported consistently following the PRISMA reporting guidelines.  
Types of included studies 
Only randomised controlled trials (RCT) of at least 10 participants, to at least one suitable augmentation treatment 
were included. 
Types of participants 
Participants must have been adults with TRD, defined as unremitted depression despite at least two courses of 
treatment of adequate dose and duration undertaken in the current episode (current best practice guidelines6). It 
has been considered that both within-class (in addition to between-class) switching of antidepressants, and 
psychological treatments are valid contributors to a TRD definition1; as such, these were permitted. Due to clear 
treatment distinctions, studies including patients with psychotic or bipolar depression were excluded.   
Types of interventions 
Patients must have been taking at least one continuation treatment prior to randomisation to a new 
(augmentation) intervention. The same eligibility criteria were employed for both continuation and augmentation 
treatments: permitted pharmacological treatments were any included in the Maudsley Treatment Inventory1 and 
psychological treatments from the NICE depression guidelines7 or those with multiple meta-analyses supporting 
use in depression. Eligible comparator treatments included pill placebo, another pharmacological agent, another 
psychological intervention, waiting list, active control, or treatment-as-usual (TAU).   
Types of outcome measures 
Primary outcome: Clinical improvement (ES) between pre- and post-treatment time points, for each eligible 
treatment/comparator arm. One efficacy measurement was selected, prioritising validated, clinician-rated 
measures of depression severity (and if not available, a patient-rated depression scale or assessment of global 
improvement if no depression symptom scale was reported). 
Secondary outcomes: A measure of adherence/compliance (e.g. any-cause trial dropout or treatment adherence 
data) and a measure of tolerability (e.g. adverse event or side effects data) were recorded where available. 
 
Search methods for identification of studies 
MEDLINE and ISI Web of Science were searched in addition to citation lists from notable papers, available reviews 
and included articles. The following medical subject headings or text word terms were used for the electronic 
database search [all fields]: (depress* OR MDD OR major depress*) AND (resistan* OR refractor* OR non-respon* 
OR nonrespon* OR un-respon* OR unrespon* OR TRD OR fail* OR inadequate OR difficult OR intractable) AND 
(augment* OR adjunct* OR add-on OR combin* OR co-administ*) AND (randomi* OR RCT) AND (treatment OR 
intervention OR trial). No language restriction was made. 
 
Data collection and analyses 
Article review and data extraction 
All search results were evaluated against inclusion criteria independently by pairs of review authors (RS, LM, RT, 
TM, VA, DT, VN, FP) with disparities addressed by consensus with additional review authors (AHY, AJC, BC). 
Following inclusion, data extraction was conducted by authors as above.   
Quality assessment  
The methodological quality assessment was examined using the Scottish Intercollegiate Guidelines Network 
(SIGN)8 and the Cochrane risk of bias (RoB)9 tools. Studies were assessed by two reviewers (rated as RoB high, low 
or unclear) for nine domains: sequence generation, allocation concealment, blinding of outcome assessors, use of 
intention-to –treat (ITT) analysis, comparability of randomised groups at baseline, inter-site differences in findings, 
the potential for selective outcome reporting and presence of for-profit bias (allegiance). Using individual criterion 
ratings, each study was given an overall RoB rating of low, moderate or high RoB (see Supplementary Table 1).  
Measures of treatment effect  
Continuous data describing treatment effectiveness were extracted (e.g. pre- and post-severity scores, or 
longitudinal change in severity scores) and presented as a standardised mean difference (Hedges’ g ES). Using a 
random effects model, meta-analyses computed a pooled ES with 95% confidence intervals (CI), p-values and the 
I2 statistic. Statistical heterogeneity was considered important if I2 exceeded 60%9, and explored using subgroups. 
The following comparisons were planned to assess the primary outcome:  
1. Pooled effects of augmentation intervention/comparator categories (i.e. psychological treatment, 
psychological comparator, pharmacological treatment and pharmacological comparator). 
2. Pooled effects of augmenters by class (e.g. SSRI, SNRI, antipsychotic, mood stabiliser). 
3. Pooled effects of individual treatment interventions within above categories. 
Additional comparisons 
We planned to explore secondary outcomes quantitatively or qualitatively, comprising: Acceptability, tolerability, 
and an exploration of pairwise active-control comparisons to provide an indicated effect of treatment versus 
comparator trial arm, validating findings against the currently considered gold standard10. 
Subgroups used to explore heterogeneity 
Planned subgroups used to explore statistical heterogeneity included study quality (RoB) and trial duration, as well 
as participant treatment-resistance definition, continuation treatments, comorbidities, depression severity, 
duration of episode and treatment setting.   
Changes made since protocol registration  
The permitted range of treatment duration was amended from 6-26 weeks to include any duration where 
expectations of clinical efficacy were reported. This was to account for the variable windows of clinical efficacy 
between different treatment mechanisms (e.g. ketamine, which has well-documented rapid antidepressant 
effects). Excluding ketamine, the MTI recommends durations of 6 weeks for full clinical effect1; therefore we 
selected to subgroup included trials of less than 6 weeks as “short-term” (this excludes rapid-onset treatments 
such as ketamine)1 and those more than 26 weeks as “long-term” treatment durations.  
 
--- Figure 1 about here --- 
 
Results 
Systematic search results 
After duplicates were removed, 2246 manuscripts from the MEDLINE and ISI Web of Science databases (all years 
to 6th February 2018) and hand searches were screened. Of 297 full texts reviewed, 39 articles describing 28 
studies were eligible for inclusion. A PRISMA flow chart presents a breakdown of the search process (Figure 1). 
 
Characteristics of Included Studies 
Within the 28 included RCTs, 5461 TRD participants were randomised. All analysed interventions were of parallel-
group studies, with ten trials (36%) conducted in North America, seven (25%) in Europe, six (21%) in Asia, four 
(14%) across multiple continents and one (4%) in South America. The mean study size was 199 (SD=270, range 20–
1293). The duration of interventions ranged from five days (ketamine11) to 18 months (long-term psychoanalytic 
psychotherapy12), with a median duration of six weeks (IQR=2).  
Characteristics of participants 
Participants studied had a median age of 45 years (IQR=4), and 66% were female. All patients analysed had 
unremitted depression despite at least two adequate treatment trials in the current episode. Fifteen studies 
defined TRD fully retrospectively (using a minimum duration of previous treatments of 4 or 6 weeks) while twelve 
required at least one unsuccessful treatment retrospectively and one prospectively. One study undertook two 
treatment trials to determine treatment-resistance fully prospectively13. Most studies did not consider 
psychological treatments to contribute to TRD definition; only Fonagy et al. required one pharmacological and one 
psychological treatment failure as a minimum TRD criteria for study entry12. Table 1 contains further details.   
Quality assessment 
Supplementary Table 1 contains the RoB ratings across criteria and studies. Twelve studies were rated as having 
a low RoB11,12,14–23, twelve had a moderate RoB24–35, and four had a high RoB13,36–38. The most common individual 
criteria rated as a high RoB were being funded and/or conducted by an industrial sponsor (twelve trials) and not 
applying or reporting an intention-to-treat analysis (seven trials). Blinding was not always maintained but was 
often maximised where possible i.e. in the ketamine trial (reportedly double-blind11), psychological trials (two out 
of three trials report blinding of outcome assessors12,18) and open label studies (all but one38 reporting blinded 
outcome raters). 
 
--- Table 1 about here --- 
 
 
Effectiveness of augmentation treatment  
There was clinical diversity in the design (see Table 1), intervention and outcomes reported (see Supplementary 
Table 2) across studies.   
 
Primary outcomes  
Pre-post meta-analyses indicated improvements in depression with all interventions examined (p < 0.001). From 
23 studies including 3246 patients, pharmacological treatments yielded an overall ES of 1.15 (95%CI 1.01-1.29, 
I2=82.7). Psychological therapies as a category comprised 3 studies totalling 276 patients, showing similar effects 
(ES=1.43, 95%CI 0.50-2.36, I2=95.3). For the majority of initial analyses conducted, severe heterogeneity limited 
the interpretability of comparisons (see Supplementary Table 3). The three studies with a high RoB contributed 
substantially to this heterogeneity, demonstrating either low36 or high13,38 outlier effect sizes and the subgroup of 
active treatments trialled for a short-term duration (lithium24, metyrapone14) showed an ES of 0.61 (95%CI 0.37-
0.85, I2=0); their removal from meta-analyses notably reduced heterogeneity. In contrast, long-term treatment 
trials of lithium15 and psychoanalytic psychotherapy12 were homogeneous (ES=0.67, 95%CI 0.44-0.90, I2=4.6) and 
did not affect heterogeneity of main analyses so were not excluded from analyses. Effects of all placebo trials (pill 
ES=0.78, psychological ES=0.94) exhibited findings similar to the sub-therapeutic duration pharmacological studies 
(ES=0.61) and consistently lower than active treatments; see Figure 2 and Table 2. All active treatment effects are 
displayed in Supplementary Figure 1 and control arms in Supplementary Figure 2.  
 
--- Table 2 about here --- 
 
 
Pharmacological treatment classes 
Pharmacological interventions without high RoB trialled for a therapeutic duration had an effect size of 1.19 
(95%CI 1.08-1.30; I2=64.6). 
N-methyl-D-aspartate (NMDA) targeting drugs showed the most consistent and large effect size of the 
pharmacological classes (ES=1.48, 95%CI 1.25-1.71, I2=0), despite the individual agents included having different 
mechanisms of action.  
Mood stabilisers demonstrated an overall effect size of 1.12 (95%CI 0.92-1.31, I2=23.6), exhibiting low 
heterogeneity only. Lithium was the most frequently investigated mood stabiliser and had a slightly smaller ES 
than the overall class without heterogeneity (3 studies, ES=1.00, 95%CI 0.81-1.20, I2=0). 
Antipsychotics also had an effect size of 1.12 (95%CI 0.98-1.26, I2=75.0), and exhibited heterogeneity likely due to 
differences between treatments within this class. Aripiprazole was the most frequently assessed antipsychotic and 
provided a consistent effect across four studies (ES=1.33, 95%CI 1.23-1.44, I2=0). 
Medications not falling into the above mechanisms were grouped together (trazodone, buspirone, thyroid 
hormone and dexmecamylamine), showing an ES of 1.36 (95%CI 1.09-1.63, I2=46.4), comparable in terms of 
heterogeneity and effect size to the other pharmacological treatments. 
Psychological treatment classes 
The overall effect size of psychological therapies (3 studies; ES=1.43, 95%CI 0.50-2.36) contained substantial 
heterogeneity (I2=95.3), likely due to different therapeutic modalities that we were not able to subgroup further 
due to lack of studies. Within this analysis, cognitive-behavioural therapy (CBT) had the highest effect size of all 
individual treatments (one study25; ES=1.74) while psychoanalytic psychotherapy had the smallest (one study12; 
ES=0.59).  
Publication bias was not apparent (detail available on request). 
  
--- Figure 2 about here --- 
 Secondary outcomes  
Active versus control (pairwise) meta-analyses 
In order to validate the pre-post method against the currently considered gold standard, we conducted pairwise 
active/control comparisons. Due to data availability, only three treatment classes were examinable. Despite 
heterogeneity of therapies and studies, these proposed that psychological treatments were more beneficial than 
usual care or an active control (3 studies, ES=0.45, 95%CI 0.09-0.81, I2=63.8). Antipsychotics showed effectiveness 
when compared to placebo (7 studies, ES=0.38, 95%CI 0.18-0.58, I2=59.4). The number of mood stabiliser studies 
was lower in the pairwise comparison than in pre-post analyses due to a paucity of placebo-controlled trials, and 
were not significantly more effective than placebo (4 studies, ES=0.13, 95%CI -0.14 to 0.39, p=0.34, I2=0).  
Tolerability and acceptability 
Tolerability and acceptability were defined differently between studies, and were not sufficiently homogeneous 
to consider quantitatively in meta-analyses.  
Eight studies reported the total number of adverse events (AEs) occurring in each arm, higher in active versus 
placebo arms for most interventions but equally between active and placebo arms in the d-cycloserine16 and 
minocycline17 trials. This rate might be heavily influenced by a large number of AEs occurring in a minority of 
patients, and of 7 studies reporting the percentage of participants experiencing at least one adverse event, most 
were similar between treatment arms. 
The highest dropout rate was in the ziprasidone intervention (41% in the lower dose arm)26. There was a >10% 
discrepancy in participant dropout between arms in this study, as well as Heresco-Levy et al. (d-cycloserine 23% 
versus placebo 11%)16 and Husain et al. (minocycline 24% versus 10% placebo)17. No dropouts were reported in 
the CBT trial arms TAU and individual CBT (two patients withdrew from group CBT)25 or from the 1-week lithium 
placebo-controlled study (either trial arm)24.  
 
Discussion 
We included 28 studies, most containing low to moderate RoB, reporting effect estimates for the most prevalent 
TRD augmentation treatment strategies, using the definition of TRD most often used in clinical practice. 
Meta-analytic estimates of treatment effects for resistant and non-resistant depression 
In contrast to TRD, progress is evolving regarding the comparative effectiveness of common treatments for MDD, 
exemplified by a recent, extensive network meta-analysis39: Cipriani et al. (2018) identified over 500 double-blind 
randomised trials of antidepressant monotherapy for MDD, in contrast with 28 we found for TRD augmentation, 
finding all to be significantly more effective than placebo. Another meta-analysis of pharmacological 
augmentation treatments for depression non-responsive to >1 antidepressant reported comparable effect sizes3. 
We anticipate smaller effect sizes within TRD populations.  The greatest pre-post effect of augmentation that we 
report is for medications targeting the NMDA receptor, comprising of ketamine (antagonist), d-cycloserine (partial 
agonist) and minocycline (antagonist). This finding supports increasing attention towards drugs acting on this 
pathway, as illustrated by a network meta-analysis of pharmacological and somatic treatments for non-responsive 
depression reporting ketamine to have the strongest short-term efficacy of treatments studied40. It is notable 
however, that this finding was based on three studies only; population or design differences between studies may 
have yielded stronger effects in these trials than if directly compared with other interventions. Ketamine produced 
the highest effect size of the NMDA medications and is particularly challenging to maintain interviewer blinding, 
although Su et al. reported the trial as double blind11. Based on a larger number of studies, our findings also 
indicate that for patients with a history of two unsuccessful treatments in the current episode, aripiprazole is 
effective, but it is important to note that all trials investigating aripiprazole had a potential allegiance effect. The 
evidence is less certain (often assessed in open label designs15,28,38) but promising for lithium. The World 
Federation of Societies of Biological Psychiatry Task Force recommends lithium as the first-line augmentation 
option for TRD, and quetiapine or aripiprazole as alternatives41; however, we identified only one randomised 
quetiapine trial in the current review (found to be non-inferior to lithium). As such, it is clear that much more work 
in this field is required.   
Effects of interventions versus placebo in randomised studies for TRD 
Even a pill placebo response is variable under some methodological conditions, suggesting that there is some small 
scope for improvement for patients with TRD without augmenting with a new active treatment. The effect size 
and confidence intervals for placebo were heterogeneous across studies (as displayed in Supplementary Figure 2), 
demonstrating that indeed there are limitations to inferring the relative effects of interventions across diverse 
investigations. Placebo and active treatment outcomes will have been influenced by a multitude of factors which 
differed across trials (including but not limited to the maintenance of blinding, analyses undertaken, inclusion 
criteria relating to comorbidities, severity, etc.). Notwithstanding, it does appear that as a whole both 
psychological and pharmacological treatments are more effective than either pill or psychological controls, even 
for already resistant patients. Specifically, the treatment classes whose pre-post confidence interval did not 
overlap with the pill placebo estimates were mood stabilisers, antipsychotics, NMDA drugs and medications with 
‘other’ mechanisms. This was not the case for psychological treatments which contained a wide confidence 
interval, or for short-term treatment durations. 
Effectiveness of psychological versus pharmacological intervention 
For MDD, psychological therapies demonstrate overall comparable effect sizes to pharmacological interventions, 
according to a meta-analysis of direct comparisons42. The most recent review investigating psychological 
treatments for TRD identified only two randomised studies, both underpowered and defining TRD loosely; one 
had found comparable benefits of CBT and antidepressants, while the other reported clinical benefits of CBT but 
not antidepressants43. The importance of building the psychological evidence base is clear and we predict that 
over the next decade growing efforts in this field will reduce current uncertainty of their effectiveness for this 
patient population44. 
Many psychological trials were excluded from the current review, as they focused on chronicity or recurrence of 
depression rather than the number of failed treatments. This limitation reflects the lack of integration between 
psychological and pharmacological fields and the difficulty in operationalising a measure of treatment response 
particularly for past psychological therapies (including treatment adequacy, adherence, dose, duration, intensity 
and other factors likely to influence outcome). The COBALT RCT has been seminal in the field, finding CBT adjunct 
to usual care as clinically effective (odds ratio of 3.26)45, but was not eligible for inclusion in the current review 
due to only requiring non-response to 6 weeks of one ongoing antidepressant. It is important to note that for most 
patients with TRD, a combination of pharmacological and psychological approaches may be the most effective 
treatment both in terms of acute response and relapse prevention46 although only pharmacological continuation 
treatments were focused on in the original studies included in this review. 
Limitations and Strengths 
This work highlights the weakness of the evidence base for augmentation treatments for TRD. Inconsistency of 
TRD definition excluded a large number of studies, and mediating and moderating factors (such as TRD or baseline 
severity, continuation treatments and case-mix of included patients) limited the ability to control confounders. 
However, 5034 participants from 23 studies exhibited consistency of findings. Limited comparable data were 
available on the tolerability and acceptability alongside effectiveness and we were not able to consider the 
influence of patient/investigator blinding, ITT analyses or allegiance effects in meta-analyses. These factors may 
have influenced effect sizes, although have not notably affected similar results in other reviews4,39. Due to the 
limited number of psychological studies included, uncertainty remains over the benefit of CBT, psychoanalytic 
therapy and mindfulness-based cognitive therapy in this population. 
Meta-analytic comparisons between treatment types have been deemed unsuitable (unless compared directly in 
original studies), but pre-post meta-analysis provides indications of effectiveness that can be compared between 
modalities. The pre-post analysis approach may show larger effect sizes due to spontaneous or natural remission, 
or patient expectations of effectiveness10 but the likelihood of this is attenuated in TRD populations who have 
experienced non-effective treatments and have a lower natural recovery rate than MDD as a whole. These also 
therefore reflect effects as seen in real-world clinical practice. Pre-post analysis has the advantage of permitting 
comparisons between different treatment types and controls, which traditional meta-analysis is not suitable for 
(e.g. drug placebo pills have a larger effect than a waiting list control4, although no waiting list controls were 
examined in the present studies). In spite of these advantages it must be highlighted that indirectly comparing 
effect sizes between treatments in this way does not account for between-study variability (including but not 
limited to sociodemographic and clinical differences between patients recruited, the adequacy and delivery of 
treatment, and other procedural and analytic distinctions).     
Clinical Implications 
There has been continued controversy surrounding the comparison of psychological and medication-based 
treatment for depression. We have not found strong evidence that either one or the other is more effective in 
TRD specifically, although we highlight an urgent need for more intensive investigation of psychological therapy 
programs. This study also illustrates that a short duration of treatment affects outcomes more than differences 
between treatment modalities. However, our results indicate that both psychological and pharmacological 
treatments are more effective than either pill or psychological control, even for already resistant patients. Far 
from being ‘lost causes’, our findings demonstrate that more therapeutic work is needed to achieve an optimal 
response for this subpopulation of patients. Specifically, clinicians should not rule out CBT if it is being delivered 
with sufficient intensity and skilled therapists25. Our findings also support previous work indicating that 
aripiprazole and, to a lesser extent, lithium are effective treatments, supporting their current recommendation as 
first-line therapies31. Although the measured effect sizes with these two pharmacotherapies are similar to other 
options, the fact that they have been more thoroughly investigated in a larger number of studies underlines their 
status as first-choice options. Although unconfirmed, even if some medication-based treatments are shown to 
possess greater efficacy overall in TRD, treatment decisions should necessarily remain a clinical judgement, in 
which clinicians need to balance difficulties with tolerability of medications in addition to the durability of effects 
and, vitally, patient preference when deciding on the most appropriate treatments to use. We continue to 
advocate pre-post meta-analyses and network meta-analyses following future primary RCTs to provide further 
assistance to clinicians for predicting the optimal treatment modality/ies for patients with TRD.  
Summary  
Despite advances in the treatment of affective disorders, both clinical response to and tolerance of current 
pharmacological agents is often poor2,47. This is particularly so for patients with TRD, for whom there is a wide 
range of treatment options that may be suitable, but very little consensus on which are the most effective and 
tolerable46. Our analyses provide both absolute (pre-post) and relative (pairwise) effect estimates for 
augmentation treatment strategies investigated for treatment-resistant depression, using the definition of TRD 
most often used in clinical practice. Based on our results, ketamine and other NMDA-targeting drugs, as well as 
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